News & Media: All

Jan 9, 2017

Philipson in Forbes: Is Disneyland the Future of Personalized Medicine?

In Tomas Philipson's latest Forbes.com commentary, he wonders whether the pricing system used by Disneyland and other amusement parks is a concept applicable to personalized medicine.

To read the complete commentary, please click here.

Jan 5, 2017

Jason Shafrin's Blog Named One of the Top 100 Economics Blogs of 2016

Precision Health Economics senior research economist Jason Shafrin's blog, "Healthcare Economist," has been named as one of the top 100 economics blogs of 2016 by Intelligent Economist. The editors write: "His blog is filled with unbiased and research driven critiques of today’s healthcare is ...

Jan 4, 2017

PHE's Anupam Jena Named One of the 60 Most Powerful People in Healthcare for 2016

Precision Health Economics is proud to announce that scientific advisor Anupam Jena, MD has been named by Becker's Hospital Review as one of the 60 most powerful people in healthcare in 2016, joining other influential leaders such as Robert Califf, Frances Collins, David Feinberg, Bill & Melinda ...

Jan 3, 2017

Jason Shafrin Interviewed in The Journal of Healthcare Contracting

PHE Senior Research Economist Jason Shafrin discusses the need for and mission of the Innovation and Value Initiative, as well as the keys to its success in the latest edition of The Journal of Healthcare Contracting. "If we find a research topic that life sciences, payers, providers are all beh ...

Dec 12, 2016

Linthicum and Shafrin Discuss the Science of Value Assessment in GEN News

PHE's Mark Linthicum and Jason Shafrin discuss advancing the science of value assessment and the mission of the Innovation and Value Initiative in the latest edition of Genetic Engineering and Biotechnology News.

To read the complete article, please click here.

Dec 9, 2016

Jason Shafrin in The Washington Post: How We Should Pay for Cures

PHE Senior Research Economist Jason Shafrin's latest Op-ed is featured in The Washington Post, as part of their "In Theory" series. The commentary, "How we should pay for cures, according to economics," examines the current complexities of drug pricing and advocates for value-based pricing struc ...

Dec 8, 2016

Precision's Jena Featured on Freakonomics Podcast

PHE Scientific Advisor Anupam Jena was recently featured on the award-winning podcast Freakonomics, as part of their "Bad Medicine: The Story of 98.6" 3-part series. Episode one addresses some of the historical mistakes produced by "trial and error" medicine, and asks whether the new era of evid ...

Dec 5, 2016

Philipson in Forbes: Assessing Healthcare Value Needs a Decentralized Approach

In Tomas Philipson's latest Forbes.com commentary, he provides a step-by-step breakdown of the steps necessary for creating a new, decentralized and scientific approach to value assessment.

To read the complete editorial, please click here.

Nov 22, 2016

Jason Shafrin in MedCity News: "Precision Medicine Will Increase Drug Prices and That's A Good Thing"

PHE Senior Research Economist Jason Shafrin details the benefits and challenges of precision medicine in a new commentary for MedCity News.

To read the complete article, please click here.

Nov 15, 2016

Precision's Shih Addresses 'Peace of Mind' Value in Multiple Sclerosis News Today

PHE Research Economist Tiffany Shih's recent study, "Reconsidering the Economic Value of Multiple Sclerosis Therapies," as published in the American Journal of Managed Care, examines "peace of mind" value represented by novel MS therapies.

Click here to read a discussion of the study, includin ...

Nov 11, 2016

Lakdawalla and Goldman in STAT News: Pharma Needs a New Prescription

Precision Health Economics founders Darius Lakdawalla and Dana Goldman contribute a new commentary for STAT News: "Election Verdict: Pharma Needs a New Prescription."

To read the complete commentary, please click here.

Nov 4, 2016

Philipson and Lakdawalla in Forbes: Rethinking FDA Approval Framework

Tomas Philipson and Darius Lakdawalla address the FDA approval framework in their latest commentary for Forbes.

For the complete article, please click here.

Nov 4, 2016

PHE's Ward, Linthicum and Silverstein in Health Affairs: Examining Barriers to Value-Based Agreements

In a new blog on the Health Affairs website, PHE's Alison Sexton Ward, Mark Linthicum and Alison Silverstein examine the regulatory and legal uncertainties existing as barriers to value-based agreements for drugs.

To read the complete blog, please click here.

Oct 31, 2016

Shafrin Discusses Obamacare on NPR's 'Here and Now'

PHE's senior research economist Jason Shafrin discusses anticipated premium price surges and the future for Obamacare on NPR's "Here and Now."

For the complete audio interview, please click here.

Oct 28, 2016

Multiple PHE Authors Featured in Latest Edition of JMCP

We are proud to announce that multiple studies by PHE authors are featured in the latest edition of the JMCP.

Readers will find "Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia," by PHE authors Ja ...

Oct 26, 2016

PHE's Jason Shafrin Discusses Value-Based Drug Pricing in HealthcareDIVE

Precision Health Economics' senior research economist Jason Shafrin discusses value-based drug pricing and the benefits for payers in HealthcareDIVE.

To read the complete article, please click here.

Oct 6, 2016

Philipson in Forbes: Why the Drug Industry and Its Critics Are Both Wrong About How R&D Spending Affects Pricing

In Tomas Philipson' latest Forbes.com commentary, he explains why the drug industry and their critics are both wrong about how R&D spending affects pricing.

To read the complete editorial, please click here.

Sep 20, 2016

Tomas Philipson Addresses UN's Access to Medicines Panel in WSJ Op-Ed

In Tomas Philipson's op-ed for the Wall Street Journal, he addresses the UN's Access to Medicines panel findings, pointing out that restricting the patent system will make it harder, not easier, for the global poor to get medicines.

To read his complete commentary, please click here.

Sep 19, 2016

Precision to Have Strong Presence at ISPOR Europe, October 29th to November 2nd, 2016

At ISPOR's 19th Annual European Congress, to be held from October 29th - November 2nd, 2016 in Vienna, Austria, Precision will have a very strong presence.

Come visit the Precision team in Booths 1000/900/1001/901!

In addition, please look for examples of our expertise in the following sessio ...

Sep 15, 2016

Goldman, Nussbaum and Linthicum in Health Affairs: Innovation Needed in Pricing and Value Measurement

In their new Health Affairs blog post, Dana Goldman, Sam Nussbaum and Mark Linthicum make the case for advancing pricing and value measurement innovation via the launch of the Innovation and Value Initiative (IVI).

To read the complete blog post, please click here.

Sep 13, 2016

Philipson Participates in AEI Panel Debating Price of Specialty Drugs

On Monday, September 12th, 2016 at AEI, health policy experts representing practitioners and industry discussed the issue of high drug prices.

On the panel, Precision's Tomas Philipson cast doubt on the claim that research and development determine pricing, arguing that in reality causality run ...

Sep 6, 2016

Philipson in Forbes: EU vs. US Cancer Care- You Get What You Pay For

In Tomas Philipson's latest Opinion for Forbes.com, he examines cancer care in the EU vs. the US, pointing out some dramatic differences in determining cost-effectiveness.

To read the complete commentary, please click here.